EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Allelic Variants of the DPYD Gene in Russian Patients with Cancer: The Results of Exome Sequencing

Denis Fedorinov iD, Vladimir Lyadov iD, Marina Lyadova, Sherzod Abdullaev iD, Ivan Sychev iD, Anna Filatova, Lavrentii Danilov, Oleg Glotov iD, Iuliia Budagova iD, Karin Mirzaev, Dmitry Sychev iD

Genes · 2026

DOI: 10.3390/genes17091082 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Genes, 2026. Verfasst von Denis Fedorinov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Feder-ation (the Federal Scientific-technical programme for genetic technologies development for 2019-2…, Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Pharmacogenetic testing of the dihydropyrimidine dehydrogenase gene (DPYD) is increasingly incorporated into clinical practice to identify patients at increased risk of fluoropyrimidine-related toxicity. However, most routine assays target a limited number of well-established variants, whereas the DPYD gene demonstrates substantial population variability and may harbor rare potentially functional alleles that are not detected by conventional targeted testing. Data describing coding and splice-region DPYD variants detectable by whole-exome sequencing in Russian oncology populations remain limited. This study aimed to characterize the frequency and distribution of common, clinically relevant, and rare DPYD variants in a Russian cohort of patients receiving fluoropyrimidine-containing chemotherapy and to compare the observed allele frequencies with European and East Asian reference populations.

Methods

Descriptive pharmacogenetic analysis was performed in 339 patients with malignant tumors treated with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT), folinic acid, fluorouracil, and oxaliplatin (FOLFOX), or folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) regimens. Whole-exome sequencing was performed using Illumina technology with exome enrichment by KAPA HyperExome and a sequencing depth of at least 100×. Sequence reads were aligned to the Genome Reference Consortium Human Build 38 (GRCh38) reference genome, germline variants were called using Genome Analysis Toolkit (GATK), HaplotypeCaller, and functional annotation was performed with Ensembl Variant Effect Predictor. DPYD variants were classified according to their population frequency, predicted functional effect, ClinVar annotations, and current pharmacogenetic recommendations. Allele and genotype frequencies were calculated and descriptively compared with Genome Aggregation Database (gnomAD) v4.1.1 Non-Finnish European and East Asian populations.

Results

Seventeen DPYD variants were identified. The most frequent alternative alleles were rs1801265 (24.93%), rs1801159 (17.70%), rs2297595 (11.06%), rs1801160 (7.08%), and rs17376848 (5.16%). Their distribution was generally closer to that observed in the Non-Finnish European population than in East Asian populations. The established reduced-function variant rs67376798 (c.2846A>T, p.Asp949Val) was detected in one heterozygous patient, corresponding to a carrier frequency of 0.29% and an allele frequency of 0.15%. The HapB3 proxy variant rs56038477 (c.1236G>A) was identified in 13 heterozygous patients, with a carrier frequency of 3.83% and an allele frequency of 1.92%; confirmation of the functional intronic variant rs75017182 would be required for definitive HapB3 assignment. Overall, rs67376798 or rs56038477 was detected in 14 patients (4.13%). In addition, rare variants with a cohort allele frequency below 1% were identified in 11 patients (3.24%). Among these, p.Thr65Ala, p.Thr65Met, p.Asn151Asp, and p.Val691Leu represented potentially relevant findings requiring further functional validation.

Conclusions

Whole-exome analysis revealed a heterogeneous spectrum of DPYD variants in the studied Russian oncology cohort, including both established pharmacogenetic markers and rare variants that would not be captured by limited targeted panels. The overall allele-frequency pattern was predominantly similar to that of European reference populations, although several rare variants demonstrated distinct distributions. These findings support the value of population-specific characterization of DPYD and suggest that expanded sequencing approaches may complement conventional pharmacogenetic testing by identifying rare potentially functional alleles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedAllelesEastern European PeopleExome SequencingGene FrequencyPolymorphism, Single NucleotideRussia

Stichwörter der Autor:innen

DPYDcancergenegeneticsgenomegenotypepharmacogeneticspharmacogenomicswhole-exome sequencing

Substanzen

Dihydrouracil Dehydrogenase (NADP)

Autor:innen und Institutionen

  • Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», 119991 Moscow, Russia.
  • Moscow Multidisciplinary Clinical Center "Kommunarka", 108814 Moscow, Russia.
  • Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education", Ministry of Healthcare of the Russian Federation, 125993 Moscow, Russia.
  • Moscow State Budgetary Healthcare Institution "Oncological Center No. 1 of Moscow City Hospital Named After S.S. Yudin, Moscow Healthcare Department", 115446 Moscow, Russia.
  • Novokuznetsk State Institute of Postgraduate Medical Education-Branch of Russian Medical Academy of Continuous Professional Education, 654005 Novokuznetsk, Russia.
  • E.M. Tareev Clinic of Rheumatology, Nephrology, and Occupational Pathology, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.

ORCID-Profile: Denis Fedorinov, Vladimir Lyadov, Sherzod Abdullaev, Ivan Sychev, Oleg Glotov, Iuliia Budagova, Dmitry Sychev

Förderung

  • Ministry of Science and Higher Education of the Russian Feder-ation (the Federal Scientific-technical programme for genetic technologies development for 2019-2…
  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Fedorinov, D., Lyadov, V., Lyadova, M., Abdullaev, S., Sychev, I., Filatova, A., Danilov, L., Glotov, O., Budagova, I., Mirzaev, K., & Sychev, D. (2026). Allelic Variants of the DPYD Gene in Russian Patients with Cancer: The Results of Exome Sequencing. Genes. https://doi.org/10.3390/genes17091082

Vancouver

Fedorinov D, Lyadov V, Lyadova M, Abdullaev S, Sychev I, Filatova A, et al. Allelic Variants of the DPYD Gene in Russian Patients with Cancer: The Results of Exome Sequencing. Genes. 2026. doi:10.3390/genes17091082

BibTeX
@article{Fedorinov2026,
  author = {Fedorinov, Denis and Lyadov, Vladimir and Lyadova, Marina and Abdullaev, Sherzod and Sychev, Ivan and Filatova, Anna and Danilov, Lavrentii and Glotov, Oleg and Budagova, Iuliia and Mirzaev, Karin and Sychev, Dmitry},
  title = {Allelic Variants of the DPYD Gene in Russian Patients with Cancer: The Results of Exome Sequencing},
  journal = {Genes},
  year = {2026},
  doi = {10.3390/genes17091082}
}
Kostenlos starten →